Weekly Investment Analysts’ Ratings Changes for Quince Therapeutics (QNCX)

Several analysts have recently updated their ratings and price targets for Quince Therapeutics (NASDAQ: QNCX):

• 6/29/2026 – Quince Therapeutics was upgraded by Lifesci Capital to “strong-buy”.
• 6/24/2026 – Quince Therapeutics was upgraded by Zacks Research to “hold”.
• 6/24/2026 – Quince Therapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $80.00 price target on the stock.
• 6/23/2026 – Quince Therapeutics is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $80.00 price target on the stock.
• 6/23/2026 – Quince Therapeutics is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $80.00 price target on the stock.
• 5/17/2026 – Quince Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/9/2026 – Quince Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.